Bli medlem
Bli medlem

Du är här


Merus N.V.: Merus to Present at the Jefferies London Healthcare Conference

UTRECHT, The Netherlands, Nov. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V.
(NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative
bispecific antibody therapeutics, today announced that Ton Logtenberg, CEO,
will present at the Jefferies London Healthcare Conference on Thursday,
November 17, 2016 at 11:20 PM GMT at the Waldorf Hilton in London, UK.

A live webcast of the Jefferies presentation will be available on the Investor
page of the Company's website. An archived presentation will be available for
90 days.

About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full
length human bispecific antibody therapeutics, referred to as Biclonics®.
Biclonics® are based on the full-length IgG format, are manufactured using
industry standard processes and have been observed in preclinical studies to
have several of the same features of conventional monoclonal antibodies, such
as long half-life and low immunogenicity. Merus' lead bispecific antibody
candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in
Europe as a potential treatment for HER2-expressing solid tumors. Merus'
second bispecific antibody candidate, MCLA-117, is being developed in a Phase
1/ 2 clinical trial in patients with acute myeloid leukemia. The Company also
has a pipeline of proprietary bispecific antibody candidates in preclinical
development, including MCLA-158, which is designed to bind to cancer stem
cells and is being developed as a potential treatment for colorectal cancer
and other solid tumors, and Biclonics® designed to bind to various
combinations of immunomodulatory molecules, including PD-1 and PD-L1.

Merus N.V.
Shelley Margetson -
+31 (0)30 253 8800

Argot Partners
Kimberly Minarovich -

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.